PA-BOOMI
Boomi™ , the intelligent connectivity and automation leader, today announced the recipients of its 2022 EMEA Partner awards, who were formally honored at Boomi’s recent EMEA Partner Summit in Amsterdam. The event brought together more than 300 attendees from Boomi partners from across the region to learn, network, and share best practices. It was also an opportunity for Boomi to recognize its partners for their innovative work.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220713005287/en/
“Our partners are trusted advisors, strategic consultants, leaders in IT and digital transformation, and innovators in the cloud infrastructure space,” said Derek Thompson, Vice President of Business Development, EMEA at Boomi. “They solve problems and proactively implement Boomi’s technology day in and day out. We’re honored to recognize the work they accomplished this past year.”
“As organizations face significant challenges to transform their business to achieve the strategic and operational objectives, enterprise integration is on top of the agenda for CIOs and CDOs,” said Jason Newman, Partner, Integration Services, Deloitte UK. “We are very proud of the work we do to consistently deliver innovative solutions to solve complex business challenges for our clients. This award is a strong testament to the highly skilled and talented people we have in the Deloitte Integration Services team and the strong partnership with Boomi.”
This year’s winners of the EMEA Partner Summit Awards include:
Innovative Project of the Year
- Global Systems Integrator (GSI): Accenture
- Systems Integrator (SI): IntegrationWorks GmbH
Solution Partner of the Year
- Global Systems Integrator (GSI): Deloitte
- Systems Integrator (SI): Cegeka
Individual Contributor Award: Mukesh Gehlot, CEO, NeosAlpha
- Highly Commended:
- Isto Kaitosaari, CTO, Integrations Group
- Guillaume Rozier, Associate Partner, Fekra
Sales and Marketing Campaign of the Year: Gambit
Services Partner Of The Year: Viseo
-
Highly Commended:
- B-Flow
- Onepoint Consulting
Emerging Markets Partner of the Year: Xitricon
Rising Star: Syscons
“As a Boomi partner, we appreciate the recognition,” said Mukesh Gehlot, CEO, NeosAlpha. “Boomi’s commitment to its partners, as well as customer success, goes above and beyond.”
Boomi recently expanded its Partner Resource Center , which provides insightful content as well as opportunities for partners to further promote their brand and value proposition to end-users through the Partner Finder. Additionally, Boomi simplified program requirements and the way partners do business by providing a clear partner onboarding path and streamlining partner training for accreditations and certifications.
Boomi has been positioned as a Leader in the Gartner® Magic Quadrant™ for Enterprise Integration Platform as a Service (EiPaaS) for eight consecutive years .
As a category-leading, global software as a service (SaaS) company with more than 20,000 customers – Boomi touts a growing user community of over 100,000 members , a worldwide network of more than 800 partners , and one of the largest arrays of global system integrators (GSIs) in the iPaaS space, which includes Accenture, Deloitte, SAP, and Snowflake, as well as the three largest cloud providers, Amazon Web Services, Google, and Microsoft, among others.
The company recently received the Gold Globee® Award in the Platform as a Service (PaaS) category, and has garnered a prestigious 5-star rating in the CRN Partner Program Guide, a definitive list of the most notable partner programs from industry-leading technology vendors that provide innovative products and flexible services through the IT channel. Boomi’s cloud-native, low-code platform helps organizations across all industries connect data applications, streamline workflows, and deliver more integrated customer experiences.
To learn more about partnering with Boomi or to find a partner from Boomi’s global ecosystem, visit https://boomi.com/partners/ .
Additional Resources
- Learn more about Boomi's Partner Program
- Read the blog post Why Connections Matter to Partners
- Learn more about The Boomi AtomSphere Platform
- Explore the Boomiverse Community
- Follow Boomi on Twitter , LinkedIn , Facebook , and YouTube
Gartner Disclaimer:
Gartner, Magic Quadrant for Enterprise Integration Platform as a Service, Eric Thoo, Keith Guttridge, Bindi Bhullar, Shameen Pillai, Abhishek Singh, September 29, 2021
Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER and Magic Quadrant are registered trademarks and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. Note: Boomi was recognized as Dell Boomi from 2014 to 2019.
About Boomi
Boomi instantly connects everyone to everything, anywhere with its cloud-native, unified, open, and intelligent platform. Boomi's integration platform as a service (iPaaS) is trusted by more than 20,000 customers globally for its speed, ease-of-use, and lower total cost of ownership. As the pioneer at fueling intelligent use of data, Boomi's vision is to make it quick and easy for customers and partners to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com
.
© 2022 Boomi, LP. Boomi, the ‘B’ logo, Boomiverse, and AtomSphere are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005287/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom